Hyperimmune Plasma in Patients With COVID-19 Severe Infection
NCT04385043
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
400
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
OTHER:
plasma hyperimmune
DRUG:
standard therapy
Sponsor
University of Catanzaro
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]